Spyre Therapeutics, Inc.
SYRE· Nasdaq
SYRESpyre Therapeutics, Inc.
Filed Nov 7, 2017 · 10-Q · 38 days after period end · 0001564590-17-022228
| Metric | Q3 2017 | Q3 2016 | Q3 2015 |
|---|---|---|---|
| Revenue | $1.26M | — | — |
| Net Income | -$7.87M | -$6.24M | -$3.41M |
| EPS Diluted | -$0.48 | -$0.47 | -$5.57 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Spyre Therapeutics, Inc. · CIK 1636282 · Engraved from SEC EDGAR
ended Sep 30, 2017 · filed Nov 7, 2017 · 38 d after period end
